Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037982 | 0.88 | HDAC1 (0.50) | ALDH1A1HTTMEN1MAPK1KMT2A | |
| SCHEMBL6037941 | 0.84 | ALDH1A1 (0.49) | ALDH1A1HTTMEN1MAPK1KMT2A | |
| SCHEMBL6037946 | 0.84 | SLC22A12 (0.44) | HTTSLC22A12MEN1MAPK1KMT2A | |
| SCHEMBL6038100 | 0.82 | SMN1; SMN2 (0.52) | ALDH1A1HTTMEN1MAPK1KMT2A | |
| SCHEMBL5280811 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HTTMEN1MAPK1KMT2A | |
| SCHEMBL6037969 | 0.82 | MTNR1A (0.47) | ALDH1A1HTTMTNR1AMTNR1BMEN1 | |
| SCHEMBL6038071 | 0.81 | ALDH1A1 (0.57) | ALDH1A1MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL5291493 | 0.81 | POLB (0.49) | ALDH1A1MTNR1AMTNR1BMAPK1 | |
| SCHEMBL6038169 | 0.80 | TSHR (0.49) | ALDH1A1MEN1KMT2A | |
| SCHEMBL5280023 | 0.80 | FFAR1 (0.46) | ALDH1A1MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | claimed |
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | ALDH1A1 781/4885HTT 846/4885SLC22A12 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.